title: Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
abstract: 3,4-Methylenedioxymethamphetamine (MDMA) has recently been hypothesized to be effective against the symptoms of Parkinson's disease. Therefore we tested the effects of MDMA-derivatives in the rotational behavioural model. Male Sprague Dawley rats were lesioned unilaterally with 6-hydroxydopamine at the medial forebrain bundle. MDMA was administered at doses of 2.5, 5.0 and 10.0 mg/kg, its derivatives N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butananamine (MBDB), 3,4-Methylenedioxy-N-ethylamphetamine (MDE) and 3,4-Methylenedioxyamphetamine (MDA) at 5.0 mg/kg respectively. All substances induced ipsilateral rotations, MDA being the most effective. MDMA induced rotations were attenuated by the selective serotonin reuptake inhibitor Citalopram but were only slightly reduced by pre-treatment with the selective serotonin synthesis inhibitor PCPA (para-chlorophenylalanine). The effects of MDMA can therefore not fully be explained by serotonin release or by dopaminergic activity of the drugs.
authors.affiliation: Neuropharmacology Institute, University of Tübingen, Germany.
authors.forename: H B
authors.initials: HB
authors.lastname: Lebsanft
authors.forename: A
authors.initials: A
authors.lastname: Mayerhofer
authors.forename: K-A
authors.initials: KA
authors.lastname: Kovar
authors.forename: W J
authors.initials: WJ
authors.lastname: Schmidt
mesh_terms: D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D015283:Citalopram / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D010134:Fenclonine / Q000494:pharmacology; D007839:Functional Laterality; D006213:Hallucinogens / Q000494:pharmacology*; D008297:Male; D008474:Medial Forebrain Bundle / Q000187:drug effects* / Q000503:physiopathology*; D023421:Models, Animal; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D016627:Oxidopamine / Q000494:pharmacology; D010300:Parkinson Disease / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012399:Rotation; D012702:Serotonin Antagonists / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology
chemical_list: D015104:3,4-Methylenedioxyamphetamine; D018663:Adrenergic Agents; D001058:Apomorphine; D015283:Citalopram; D004298:Dopamine; D010134:Fenclonine; D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D016627:Oxidopamine; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; C051570:N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine; C051800:3,4-methylenedioxyethamphetamine